Skip to main content
. Author manuscript; available in PMC: 2022 Oct 15.
Published in final edited form as: ACS Chem Biol. 2021 May 26;16(10):1985–1993. doi: 10.1021/acschembio.1c00212

Figure 2.

Figure 2.

Co-delivery of OVA-STALs (OVA-LP-CD22L) and PLGA-R nanoparticles induce greater tolerance to liposomal OVA. (A) C57BL/6J mice (n = 16) were immunized on day 0 with the indicated nanoparticle treatments i.v. and then challenged i.p. with OVA/Alum on day 14 and fOVA on day 35. Data were pooled from three independent experiments. (B) C57BL/6J mice (n = 5) were immunized on days 0 and 14 with the indicated nanoparticle treatments i.v. and then challenged i.p. with OVA/Alum on day 28 and fOVA on day 49. Results are representative of two independent experiments. PLGA-R nanoparticles contained 100 μg of rapamycin.35 Mice were bled weekly after the treatment, and IgG1 titers were assessed for OVA. Blood from naïve mice was used as a control to normalize the data. Normalized titers were obtained by dividing the observed titers with the mean titer from naïve mice. All data represent the mean ± SEM. All statistical analyses were performed on raw data using two-way ANOVA with Tukey’s post-test (**** P ≤ 0.0001; ***P ≤ 0.001; ** P ≤ 0.01; *P ≤ 0.05).